Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey.
Neurol Sci
; 43(5): 3305-3312, 2022 May.
Article
in En
| MEDLINE
| ID: mdl-35006445
ABSTRACT
BACKGROUND:
Despite development of new therapies, migraine remains an undertreated illness. It is important to understand patients' preferences and perceptions of using a certain therapy. We present data from a nationwide Lithuanian survey of patients' experience using erenumab for the treatment of high frequency episodic and chronic migraine.METHODS:
An anonymous internet survey was distributed on February-March 2021 to the members of Migraine Association of Lithuania. All adult respondents who reported using at least one dose of erenumab were included in the study.RESULTS:
Out of 145 respondents, 75.2% had chronic migraine, and 31.7% had medication overuse headache. Patients received an average of 6 (IQR 4-9) erenumab doses. 93.1% respondents found erenumab effective, and 72.6% experienced improvement during the first month. MHDs were reduced by 9.8 (SD 6.0) (P < 0.001), and MMDs by 7.2 (SD 5.2) days (P < 0.001). 78.6% respondents achieved ≥ 50% reduction and 47.6% achieved ≥ 75% reduction of MMDs. 13.8% patients indicated a wearing-off effect during the treatment course, and 37.8% - some wearing-off between injections. Constipation was the most frequent adverse event (32.6%). 47.2% of patients who had a positive erenumab effect and discontinued treatment experienced migraine rebound in 6 (SD 2.0) weeks.CONCLUSION:
Erenumab is perceived as an effective and safe treatment. Further studies are needed to investigate a post-cessation deterioration of achieved improvement. HIGHLIGHTS ⢠Vast majority of patients experience stable or increasing effect of erenumab. ⢠Erenumab efficacy usually becomes evident during the first month of treatment. ⢠Erenumab is perceived significantly better than non-specific preventive medications. ⢠Almost 40% of patients experienced some wearing-off between injections. ⢠Almost half of patients experience migraine rebounds after treatment cessation.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Headache Disorders, Secondary
/
Migraine Disorders
Aspects:
Patient_preference
Limits:
Adult
/
Humans
Language:
En
Journal:
Neurol Sci
Journal subject:
NEUROLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Lithuania